References
- Schrappe M, Reiter A, Zimmermann M, et al. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Münster. Leukemia. 2000;14:2205–2222.
- Gianfaldoni G, Mannelli F, Bencini S, et al. Peripheral blood blast clearance during induction therapy in acute myeloid leukemia. Blood. 2008;111(3):1746–1747.
- Short NJ, Benton CB, Chen H-C, et al. Peripheral blood blast clearance is an independent prognostic factor for survival and response to AML induction chemotherapy. Am J Hematol. 2016;91(12):1221–1226.
- Schuurhuis GJ, Heuser M, Freeman S, et al. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2018;131(12):1275–1291.
- Zuckerman T, Ganzel C, Tallman MS, et al. How I treat hematologic emergencies in adults with acute leukemia. Blood. 2012;120(10):1993–2002.
- Oberoi S, Lehrnbecher T, Phillips B, et al. Leukapheresis and low-dose chemotherapy do not reduce early mortality in acute myeloid leukemia hyperleukocytosis: a systematic review and meta-analysis. Leuk Res. 2014;38(4):460–468.
- Röllig C, Ehninger G. How I treat hyperleukocytosis in acute myeloid leukemia. Blood. 2015;125(21):3246–3252.
- Mamez A-C, Raffoux E, Chevret S, et al. Pre-treatment with oral hydroxyurea prior to intensive chemotherapy improves early survival of patients with high hyperleukocytosis in acute myeloid leukemia. Leuk Lymphoma.. 2016;57(10):2281–2288.
- Bertoli S, Picard M, Bérard E, et al. Dexamethasone in hyperleukocytic acute myeloid leukemia. Haematologica. 2018;103(6):988–998.
- Cerrano M, Itzykson R. New treatment options for acute myeloid leukemia in 2019. Curr Oncol Rep. 2019;21(2):16.
- Dechartres A, Chevret S, Lambert J, et al. Inclusion of patients with acute leukemia in clinical trials: a prospective multicenter survey of 1066 cases. Ann Oncol. 2011;22(1):224–233.
- Döhner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115(3):453–474.
- Cokic VP, Beleslin-Cokic BB, Tomic M, et al. Hydroxyurea induces the eNOS-cGMP pathway in endothelial cells. Blood. 2006;108(1):184–191.
- Ritch PS, Occhipinti SJ, Cunningham RE, et al. Schedule-dependent synergism of combinations of hydroxyurea with adriamycin and 1-beta-D-arabinofuranosylcytosine with adriamycin. Cancer Res. 1981;41(10):3881–3884.
- Grimwade D, Hills RK, Moorman AV, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116(3):354–365.